<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410083</url>
  </required_header>
  <id_info>
    <org_study_id>JP_CLN_01</org_study_id>
    <nct_id>NCT02410083</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Efficacy of Combination Formula of Aspirin Plus Clopidogrel in Patients With Coronary Stent</brief_title>
  <official_title>Multicenter, Randomized, Open Study, Investigator-initiated Trial for Comparison of Eight Weeks Efficacy and Tolerability of Clopirin and Clopidogrel With Aspirin in Korean Patients With Post-Percutaneous Coronary Artery Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study in to evaluate efficacy and tolerability of Clopirin and
      clopidogrel with aspirin in Korean Patients with post-percutaneous coronary artery
      intervention.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% inhibition =△Purinergic receptor, G-protein coupled, 12 Reaction Units(PRU)/ Pretreatment PRU</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>△ PRU = Post treatment PRU - Pre treatment PRU</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>△ ARU = Post treatment Aspirin resistance unit(ARU) - Pre treatment ARU</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">448</enrollment>
  <condition>ANEURYSM CORONARY ARTERY</condition>
  <arm_group>
    <arm_group_label>Clopirin 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopirin single-administration. Before this clinical trial Clopidogrel/Aspirin co-administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel/Aspirin co-administration 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel-aspirin co-administration. Before this clinical trialClopidogrel/Aspirin co-administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopirin 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopirin single-administration. Before this clinical trial Aspirin single-administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel/Aspirin co-administration 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel-aspirin-co-administration. Before this clinical trial Aspirin single-administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopirin 1</intervention_name>
    <arm_group_label>Clopirin 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel-Aspirin(co-administration) 1</intervention_name>
    <arm_group_label>Clopidogrel/Aspirin co-administration 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopirin 2</intervention_name>
    <arm_group_label>Clopirin 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel-Aspirin(co-administration) 2</intervention_name>
    <arm_group_label>Clopidogrel/Aspirin co-administration 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 3 months, the patient who were the administration of aspirin or the
             co-administration of clopidogrel-aspirin coronary artery patients after treated with
             Percutaneous Coronary Intervention(PCI) that have safety progress.

          -  Korean men and women between the age of 20 and 85

          -  Patients who understand the study requirements, are willing to comply with all study
             procedures and have provided written informed consent.

        Exclusion Criteria:

          -  Patients who were not treated with PCI or intended to treat with PCI but failed.

          -  Patients who were taking or had taken other antiplatelet or anticoagulant for more
             than 2 weeks within the prior 30 days.

          -  Patients who had a history of alcohol abuse or intoxication.

          -  Patients who had hypersensitivity to clopidogrel or aspirin.

          -  Patients who had severe hepatic dysfunction aspartate aminotransferase(AST) or alanine
             aminotransferase(ALT) &gt; 3 times upper normal reference values.

          -  Patients who had blood coagulation disorders, uncontrolled severe hypertension, active
             bleeding, or history of severe bleeding, such as intracranial hemorrhage or ulcer
             bleeding - surgery within 48hr, platelet counts below 50,000/mm3 in laboratory tests.

          -  Patients who were pregnant, breastfeeding.

          -  Patients who were not using effective methods of contraception. (proper contraception
             : hormonal contraception, condom, intrauterine device, spermicide)

          -  Patients who medically, psychologically had investigational product administration's
             prohibition.

          -  Patients who were not participated in this clinical trial decided by other
             investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-soo Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <last_update_submitted>March 12, 2017</last_update_submitted>
  <last_update_submitted_qc>March 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Coronary Aneurysm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

